US Patent:
20130210810, Aug 15, 2013
Inventors:
Rigel Pharmaceuticals, Inc. - , US
Hui Li - Santa Clara CA, US
Haoran Zhao - Foster City CA, US
Rao Kolluri - Foster City CA, US
Kin Tso - San Francisco CA, US
John Ramphal - Union City CA, US
Shihai Gu - Union City CA, US
Carlos Valdez - San Ramon CA, US
Jing Zhang - Mercer Island WA, US
Emily Stauffer - San Francisco CA, US
Matthew Duncton - San Bruno CA, US
Salvador Alvarez - Fremont CA, US
Assignee:
RIGEL PHARMACEUTICALS, INC. - South San Francisco CA
International Classification:
A61K 31/506
A61K 31/55
A61K 31/538
A61K 31/5377
US Classification:
51421706, 544324, 514275, 544122, 5142358, 540601, 435184, 544323, 5142338, 544105, 5142305
Abstract:
This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.